I was excited to dive with you, into the groundbreaking strides in #lungcancer treatment unveiled this year! Collaborative discussions like these drive innovation & progress. Thanks for having me #SBOC23 🇧🇷#LungCancerAwareness #LCSM

#IEO_Polmone 🔥IEO

🛎 just published in NEJM our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements. A major advance for our patients! 🔗nejm.org/doi/full/10.10…

🆕ADC landscape…from the analyst’s couch, investigating innovation in the clinical pipeline across 5 design levers: target, payload, antibody, linker & conjugation method “A one-size fits all” technology is unlikely to emerge in the near-term! nature.com/articles/d4157…

Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic Daniel Tan SingHealth Pankaj Kumar Panda

Fantastic discussion on the dynamic landscape of EGFR mutant #LungCancer with Ross Soo and his team at NUH in Singapore! The pace of evolution demands collaboration and cross-fertilization. Exciting times ahead! 🚀 #LCSM

#ASCO24 is ready to start soon! Here, my top🔟 selection with explanation, among the #LungCancer abstracts #LCSM 🧵

Long-term PFS analysis is an endpoint that fills me with enthusiasm for the progress of medicine. It's a revolution in favor of our patients, where the magnitude of clinical benefit continues to advance. #ASCO24 #LCSM

As IEO , Italians 🇮🇹, e strong believers of oncology progress worldwide, WE are all with you Giuseppe! G Curigliano MD PhD ESMO - Eur. Oncology Paolo Tarantino Umberto Malapelle Christian Rolfo Dario Trapani

🦋Today, the robust clinical development of Amivantamab for EGFR-mutant NSCLC adds a new chapter looking towards a stronger future. Soon, the Paloma-3 study will be discussed by Natasha Leighl. Honored to have been part of this significant milestone #ASCO24

I echo 🇮🇹 the AIOM and fully support Giuseppe Curigliano (G Curigliano MD PhD) for ESMO President 2027-28. I urge all medical oncologists & ESMO - Eur. Oncology members worldwide to vote for Prof Curigliano. Every vote counts‼️ click.mail.esmo.org/?qs=bd4c374814… IEO

ETOP IBCSG Partners Foundation 2nd ADCs Workshop in Zurich🇨🇭 It was a pleasure to be part of this meeting, alongside many friends, colleagues, & experts from around the world, looking forward to the development of these drugs in clinical setting #CancerResearch

Nella rubrica "TG4 medicina" un'intervista al Prof. Spaggiari, Dir. Programma Polmone IEO, per parlare di prevenzione, diagnosi e cura del tumore al polmone.💙 Per guardare l’intervista👉shorturl.at/frVdZ

Congrats Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ 🚀

Congrats Dr Passaro IEO

#PressRelease 🚨HERthena-Lung2 Another opportunity for our patients in the field of resistant EGFR-mutant #lungcancer. We are making significant strides to discuss these results soon in the scientific community and support progress. #Innovation EGFR Resisters EGFR Positive Lung Cancer UK #LCSM

Always a pleasure, exciting, & inspiring to keep studying and discussing EGFR-mutant #LungCancer with my dear friend Umberto, pushing ourselves to expand our knowledge and skills. Raising the bar remains our goal, always striving to offer the best care for our patients

🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀 jnj.com/media-center/p…

Major Breakthrough Announced - MARIPOSA Study Results - Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ (IEO) Dr. Amy C. Moore oncodaily.com/blog/219560 #Health #Medicine #Cancer #OncoDaily #Oncology #MARIPOSA #Research #MedX

Honored to host the 20th International Preceptorship on Lung Cancer at IEO - Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ oncodaily.com/url/239996 #Cancer #LCSM #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology